<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24346908</article-id>
      <article-id pub-id-type="pmc">3876011</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20132295</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Optic neuritis due to immunobiologics: first Brazilian case report<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Neurite &#xF3;ptica por imunobiol&#xF3;gico: relato do primeiro caso
brasileiro</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>da Silva</surname>
            <given-names>Luiz Gustavo Martins</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sasso</surname>
            <given-names>Let&#xED;cia Soares</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nelli</surname>
            <given-names>Carlos Jos&#xE9;</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bernardes Filho</surname>
            <given-names>Fred</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Abreu</surname>
            <given-names>Marilda Aparecida Milanez Morgado</given-names>
          </name>
          <xref ref-type="aff" rid="aff05">5</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, Specialist in Dermatology - Dermatology Service - Presidente
Prudente Regional Hospital - Universidade do Oeste Paulista (HRPP-UNOESTE) - Presidente
Prudente (SP), Brazil.</aff>
      <aff id="aff02"><label>2</label> MD, Specialist in Ophthalmology - Ophthalmology Service - Presidente
Prudente Regional Hospital - Universidade do Oeste Paulista (HRPP-UNOESTE) - Presidente
Prudente (SP), Brazil.</aff>
      <aff id="aff03"><label>3</label> MD, Assistant Professor, Dermatology Service - Presidente Prudente
Regional Hospital Universidade do Oeste Paulista (HRPP-UNOESTE) - Presidente Prudente
(SP), Brazil.</aff>
      <aff id="aff04"><label>4</label> MD, Graduate student, Professor Rubem David Azulay Institute of
Dermatology of Rio de Janeiro Santa Casa da Miseric&#xF3;rdia Hospital (IDPRDA - SCMRJ) - Rio
de Janeiro (RJ), Brazil.</aff>
      <aff id="aff05"><label>5</label> MD, Head of Dermatology Service at the Presidente Prudente Regional
Hospital - Universidade do Oeste Paulista (HRPP-UNOESTE) - Rio de Janeiro (RJ),
Brazil.</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Luiz Gustavo Martins da Silva, Avenida Ant&#xF4;nio Borges
de Queiroz, 162 - Centro, 14730-000 - Monte Azul Paulista - SP, Brazil. E-mail:
<email>luizgustavodermatologia@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>6 Suppl 1</issue>
      <fpage>162</fpage>
      <lpage>165</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>11</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>3</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The change in immunological response obtained by immunobiologics has brought a new
paradigm to the treatment of immune-mediated disorders. As a result of their
efficacy, there is a positive impact on the quality of life of patients. However,
severe side effects, such as demyelination of cerebral or peripheral nerves, have
been reported. After review of literature using PubMed and MEDLINE data from 2000 to
2012, we identified the cases correlating the biological uniterms and optic neuritis.
This article reports the first Brazilian optic neuritis case associated with the use
of immunobiologics. This publication is justified by the rarity of the disease and
atypical therapeutical evolution.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A mudan&#xE7;a da resposta imunol&#xF3;gica, obtida pelos imunobiol&#xF3;gicos, trouxe um novo
paradigma no tratamento das doen&#xE7;as imuno-mediadas. Pela sua efic&#xE1;cia, trazem impacto
positivo na qualidade de vida dos pacientes. Entretanto, efeitos colaterais graves,
como desmieliniza&#xE7;&#xE3;o cerebral ou nos nervos perif&#xE9;ricos, foram relatados. Ap&#xF3;s
revis&#xE3;o da literatura usando o banco de dados do PubMed e da MEDLINE de 2000 a 2012,
identificamos os casos correlacionando os unitermos biol&#xF3;gicos e neurite &#xF3;ptica. Este
artigo relata o primeiro caso brasileiro de neurite &#xF3;ptica associado ao uso de
imunobiol&#xF3;gico. Justifica-se esta publica&#xE7;&#xE3;o pela raridade e pela evolu&#xE7;&#xE3;o
terap&#xEA;utica at&#xED;pica.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Optic neuritis</kwd>
        <kwd>Psoriasis</kwd>
        <kwd>Tumor necrosis factor-alpha</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Psoriasis is a chronic inflammatory disease of the skin and articulations,
immunologically mediated, with a genetic basis and great polymorphism with clinical
expression.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref></sup> Of universal occurrence, it affects men and women
equally. Around 25% of all patients require systemic treatment.<sup><xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup>
Among the options for systemic treatment, there is the immunobiologics group. These are
indicated in case of moderate to severe psoriasis that is recalcitrant, when there is
contraindication, intolerance or failure of classical systemic therapy, as well as in
patients with severe quality of life deterioration. These medications of protein rich
nature interfere in an infrequent and specific way with the immune system. They are
extremely potent in the treatment of psoriasis and other inflammatory diseases. However,
its long-term effect remains unknown. Adverse effects, such as reactivation of
infectious diseases (like tuberculosis), development of anti-DNA antibodies and
lupus-like syndromes, hematological alterations, congestive cardiac insufficiency and
demyelinating diseases have been described. The impact of these side effects on
treatment feasibility has not been completely established yet.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup>
</p>
      <p>The objective of this study is to report the case of a patient with extensive psoriasis
vulgaris who, upon receiving treatment with infliximab, developed optic neuritis and
worsening of sight in the affected eye, with no improvement after 3 years of follow-up.
This is the first Brazilian case of optic neuritis associated with the use of
immunobiologics. </p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A female, 62-year-old patient, white, widow, retired housekeeper, originally from
Presidente Prudente - SP was under treatment for psoriasis vulgaris in plaques, which
had started 9 years ago. She was hypertensive, a condition controlled with the daily use
of captopril. She used low potency corticosteroids and topic moisturizers, acitretin and
methotrexate orally, but there was no response to these treatments. The use of
immunobiologics was subsequentely prescribed. No <italic>Psoriasis Area and Severity
Index</italic> (PASI) or the Life Quality Index reports were available. Previous
routine exams (PPD, chest radiography, complete blood count, biochemical profile and
liver enzymes) did not show alterations. Live virus vaccination was not advised. Three
intravenous infusions of diluted infliximab, at 5mg/kg, were applied in 3 hours and
repeated 2 and 6 weeks later. Three days after the third infusion, the patient presented
low visual acuity in the left eye, which required an emergency appointment with an
ophthalmologist of a private clinic in the city of Presidente Prudente. At the clinical
examination, lowering of visual acuity (counting of fingers at 3 meters) and blurring of
peripheral region of the optic disc were noticed during fundoscopy. Optic neuritis was
then hypothesized and she was submitted to retinography. The findings confirmed the
proposed hypothesis (<xref ref-type="fig" rid="f01">Figure 1</xref>). The patient was
referred to the emergency ophthalmologic center at the Regional Hospital of Presidente
Prudente - SP, where the same findings were confirmed. Immediate hospitalization was
decided and pulse therapy started with intravenous methylprednisolone, without previous
prescription of oral corticosteroids. Head tomography was done to rule out other causes,
such as tumors and cerebrovascular accident, with normal results (<xref ref-type="fig" rid="f02">Figure 2</xref>). To better evaluate the optic nerve and exclude other
sources of demyelination (common in multiple sclerosis cases), a head MRI was performed,
which found a hypersignal of the left optic nerve in comparison with the right optic
nerve in T2. This supported the diagnostic hypothesis of optic neuritis in the left eye
(<xref ref-type="fig" rid="f03">Figure 3</xref>). To objectively translate the sight
alterations felt by the patient, a visual campimetry was performed, which showed a
normal visual field for the right eye and alterations in the left eye: dense cecocentral
absolute scotoma, with relative augmentation with smaller targets (<xref ref-type="fig" rid="f04">Figure 4</xref>). The central target only presented an island of peripheral
vision, localized on the lower hemifield. The computerized visual field exam, central
30-2 threshold test revealed the following: Right eye: average sensitivity of visual
field normal for this age bracket. Left eye: (MD = -1.49 dB) &gt; blind spot with
relative growth. CPSD = 2.46 dB, P&lt; 10%, indicating there is a localized defect which
occurs in less than 10% of the normal population. The collaboration of the patient was
reasonably good. Variations in answers in 10 standard sites studied were normal
(SF=1.91dB). After 3 years of follow-up, there was no improvement of the patient's
visual acuity. </p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Retinography of the left eye showing blurring of the optic disc peripheral region,
discrete disc paleness and dilation of disc capillaries, without retina detachment
or breakages</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0162-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Head MRI with no alterations suggesting cerebrovascular accident or tumors</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0162-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>MRI &#x2013; head coronal section, showing the left optic nerve (marked with purple
circle) with hypersignal in comparison with the right optic nerve in T2</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0162-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Campimetry or visual field exam showing blind spot with parameter alteration (CPSD
= 2.46 db, P&lt; 10%), which indicates there is a localized defect</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0162-g04"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The biological agents are first-line drugs, and can be considered as the first
therapeutic option in selected cases, especially for patients with severe psoriatic
arthritis.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r05">5</xref></sup> Due to its
efficacy in psoriasis treatment, they cause great impact on the quality of life of
patients, promoting not only physical improvement but also psychosocial
well-being.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r06">6</xref></sup> There is,
however, and it must be remembered, the possibility of severe adverse effects. The
majority of patients with optic neuritis, with partial or no improvement, were in older
age groups.<sup><xref ref-type="bibr" rid="r07">7</xref>,<xref ref-type="bibr" rid="r08">8</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup> Pulse therapy with 1g of
methylprednisolone for 3 days is always indicated for optic neuritis and can be
associated with corticotherapy with 1mg/kg/day of oral prednisone.<sup><xref ref-type="bibr" rid="r07">7</xref>,<xref ref-type="bibr" rid="r08">8</xref></sup>
However, monotherapy with oral corticoids should be avoided, for it does not positively
affect the recovery speed and is associated with a higher recurrence rate.<sup><xref ref-type="bibr" rid="r10">10</xref></sup> The risk-benefit evaluation of biologics
use is mandatory. It is the first case of optic neuritis caused by immunobiologics in a
patient with psoriasis vulgaris, as the other cases reported were of patients with
psoriatic arthritis. This is also the first case of optic neuritis associated with the
use of infliximab prescribed for psoriasis, since in the other cases the drugs used were
etanercept and adalimumab.<sup><xref ref-type="bibr" rid="r07">7</xref></sup>
</p>
      <p>Two points should be emphasized: the first is the fact that the referred patient is in
an older group, over 60 years of age, than the other patients reported. The second is
the progression of the disease. Our patient had loss of visual acuity with no recovery
after 3 years of follow-up, while the younger patients had a higher rate of
recovery.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <p>* Work performed at Presidente Prudente Regional Hospital - Universidade do Oeste
Paulista (HRPP-UNOESTE) - Presidente Prudente (SP), Brazil.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="book">
          <source xml:lang="pt">Consenso Brasileiro de Psor&#xED;ase 2009</source>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
          <year>2009</year>
          <size units="pages">115 p.</size>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Griffiths</surname>
              <given-names>CEM</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>JNWN</given-names>
            </name>
          </person-group>
          <chapter-title>Psoriasis</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Burns</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Breathnach</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <source>Rook's Textbook of Dermatology</source>
          <edition>8th. ed</edition>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Wiley Blackwell</publisher-name>
          <fpage>20.1</fpage>
          <lpage>20.60</lpage>
          <year>2010</year>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duarte</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Chehin</surname>
              <given-names>FB</given-names>
            </name>
          </person-group>
          <article-title>Moderate to severe psoriasis treated with infliximab - 53 patients:
patients profile, efficacy and adverse effects</article-title>
          <source>An Bras Dermatol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>257</fpage>
          <lpage>263</lpage>
          <pub-id pub-id-type="pmid">21603808</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torres</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Velho</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Sanches</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Selores</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis in the era of biologics</article-title>
          <source>Acta Med Port</source>
          <year>2010</year>
          <volume>23</volume>
          <fpage>493</fpage>
          <lpage>498</lpage>
          <pub-id pub-id-type="pmid">20654269</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loyola</surname>
              <given-names>AJC</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>LCM</given-names>
            </name>
            <name>
              <surname>Chaibub</surname>
              <given-names>SCW</given-names>
            </name>
            <name>
              <surname>Ximenes</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Infliximab in treatment of severe psoriatic arthritis</article-title>
          <source>An Bras Dermatol</source>
          <year>2005</year>
          <volume>80</volume>
          <fpage>535</fpage>
          <lpage>537</lpage>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diamantino</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Future perspectives in the treatment of psoriasis: news in biological
therapies</article-title>
          <source>Acta Med Port</source>
          <year>2011</year>
          <volume>24</volume>
          <fpage>997</fpage>
          <lpage>1004</lpage>
          <pub-id pub-id-type="pmid">22713194</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tristano</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Neurological adverse events associated with anti-tumor necrosis factor
alpha treatment</article-title>
          <source>J Neurol</source>
          <year>2010</year>
          <volume>257</volume>
          <fpage>1421</fpage>
          <lpage>1431</lpage>
          <pub-id pub-id-type="pmid">20495815</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Castellanos</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Infliximab and anterior optic neuropathy: case report and review of
the literature</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>2010</year>
          <volume>248</volume>
          <fpage>283</fpage>
          <lpage>287</lpage>
          <pub-id pub-id-type="pmid">19916016</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simsek</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Erdem</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pay</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sobaci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dinc</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Optic neuritis occurring with anti-tumor necrosis factor
therapy</article-title>
          <source>Ann Rheum Dis</source>
          <year>2007</year>
          <volume>66</volume>
          <fpage>1255</fpage>
          <lpage>1258</lpage>
          <pub-id pub-id-type="pmid">17456525</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kanski</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <chapter-title>Neuroftalmologia</chapter-title>
          <person-group person-group-type="author">
            <name>
              <surname>Kanski</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <source xml:lang="pt">Oftalmologia Cl&#xED;nica</source>
          <edition>6 ed</edition>
          <publisher-name>Elsevier</publisher-name>
          <year>2008</year>
          <fpage>785</fpage>
          <lpage>793</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
